Regulation (EEC) No 2309/93

Regulation (EEC) No 2309/93
Title	Regulation (EEC) No 2309/93
Type	Regulation
Adopted	1993
Jurisdiction	European Union
Number	2309/93

Regulation (EEC) No 2309/93 established a centralised procedure for the authorisation of medicinal products within the European Community and set up the legal basis for a specialised agency to evaluate pharmaceuticals. It provided harmonised rules for marketing authorisation, pharmacovigilance and the approval of biotechnology-derived medicines, influencing subsequent instruments such as regulations and directives adopted by the European Parliament and the Council of the European Union. The measure interacted with institutions including the European Commission, national competent authorities of Member States, and eventually the European Medicines Agency.

Background and legislative context

Adopted in the early 1990s amid evolving internal market integration, the regulation responded to initiatives by the Delors Commission and legislative dynamics in the European Parliament and Council of the European Union. It built on earlier instruments such as Directive 65/65/EEC and Directive 75/319/EEC, reflecting debates involving stakeholders like the European Federation of Pharmaceutical Industries and Associations and advocacy from national regulators such as the Medicines and Healthcare products Regulatory Agency and the Agence nationale de sécurité du médicament et des produits de santé. Internationally, it aligned with frameworks discussed at the World Health Organization and negotiations involving the World Trade Organization.

Scope and key provisions

The regulation defined the scope for centralised marketing authorisation covering products derived from biotechnology and certain high-tech therapies, setting criteria that affected applicants including multinational firms from the United States, Japan, and Switzerland. It specified requirements for quality, safety and efficacy dossiers, clinical trial data submission standards shaped by precedents from the Declaration of Helsinki and guidance influenced by the European Conference of Pharmaceutical Regulatory Authorities. Provisions established timelines, application formats, and conditions for authorisation suspension, revocation or variation, interacting with patent considerations under the European Patent Convention and market exclusivity regimes influenced by the Agreement on Trade-Related Aspects of Intellectual Property Rights.

Institutional framework and procedures

The regulation created a central evaluation mechanism within a body that evolved into the European Medicines Agency, detailing roles for a Committee for Proprietary Medicinal Products and coordination with national agencies such as the Bundesinstitut für Arzneimittel und Medizinprodukte, the Instituto Nacional de Productos Sanitarios, and the Agenzia italiana del farmaco. It mandated scientific committees, rapporteur and co-rapporteur processes, and procedures for referrals to the European Commission for final decision-making, echoing decision-making structures seen in instruments of the Council of Europe and administrative law practice in the Court of Justice of the European Union.

Impact on medicinal product approval and market authorisation

By creating a single marketing authorisation valid across Member States, the regulation substantially altered submission strategies for companies like GlaxoSmithKline, Roche, Novartis, Pfizer, and Sanofi. It accelerated central review for advanced therapies such as recombinant proteins, monoclonal antibodies and gene therapies developed by firms including Genentech and Amgen. The harmonised pathway influenced clinical development planning, influenced licensing deals practiced by AstraZeneca and Bayer, and shaped pharmacovigilance obligations similar to post-marketing surveillance models used by the Food and Drug Administration. The regulation contributed to market integration affecting stakeholders across Benelux, Nordic countries, and Mediterranean region Member States.

Amendments, repeal and successors

Over time the regulation was amended and its functions were subsumed into successive EU law instruments and institutional reforms, leading to comprehensive frameworks reflected in later regulations enacted by the European Parliament and the Council of the European Union. The development of the European Medicines Agency and the adoption of newer Community rules on pharmacovigilance, clinical trials and advanced therapy medicinal products updated procedures initially established in the regulation, while legal reforms responded to rulings by the Court of Justice of the European Union and policy drives from the European Commission under successive Presidents.

Controversies and legal challenges

The centralised procedure prompted controversy involving trade associations, patient groups such as European Patients' Forum, and national industry bodies over access, intellectual property and regulatory sovereignty. Legal challenges reached administrative and judicial forums, with disputes referencing principles litigated before the Court of Justice of the European Union and debates in the European Parliament committees. Contentious topics included data transparency, benefit–risk assessment for biotechnology medicines, and the balance between market authorisation speed and post-authorisation safety oversight, subjects that engaged stakeholders including Health Technology Assessment bodies and professional associations across Member States.

Category:European Union regulations Category:Pharmaceutical regulation Category:European Medicines Agency